What is CNTB's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.05B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CNTB?

P/E (TTM) is n/a and 52-week range is $0.85 to $3.82 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CNTB figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CNTB?

The company profile lists revenue (TTM) near $3M, net income (TTM) near $-4.78B, EPS (TTM) near $-1.20 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Connect Biopharma Holdings Ltd based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 55.7M shares outstanding, ISIN KYG235491019 when available from company profile and filing metadata.

Connect Biopharma Holdings Ltd

$CNTB

Health Care · Biotechnology

IR Run Scenarios

$0.87

-1.21%

Connect Biopharma Holdings Ltd

$CNTB

Health Care · Biotechnology

IR Run Scenarios

$0.87

-1.21%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 64 full-time employees. The company went IPO on 2021-03-19. The firm is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The firm has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.

Employees

64

Website

www.connectbiopharm.com

IPO

2021-03-19

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

KYG235491019

Headquarters

San Diego, California, US

Shares outstanding

55.7M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

54.87%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 64 full-time employees. The company went IPO on 2021-03-19. The firm is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The firm has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.

Employees

64

Website

www.connectbiopharm.com

IPO

2021-03-19

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)